Up to 80% of breast cancer deaths occur in patients with tumors that express estrogen receptor-alpha, according to a study published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
